ArticleJournal for immunotherapy of cancer2017
Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy.
Article in Journal for immunotherapy of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01416831 (Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation), which is not on this map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma
Who cites it
48 citing papers in PubMed, 79 citations in OpenAlex.
- Nasal Nanoparticle Vaccine Induces a Cross-Strain T-Cell Immunity AgainstPharmaceutics · 2026Article
- Autophagy Orchestrates Anti-Tumor Immunity to Enhance Chemosensitivity via the FBXW2/C/EBPβ/TIMP-2 Axis in Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Multiparametric Flow Cytometry Panel for Characterization of Mouse T Cell Differentiation and NK Cell Maturation Following Inflammatory Challenge.Methods and protocols · 2026Article
- Fluorination augments tumor engagement and antitumor immunity of a D-peptide-based radiotheranostic agent for combinatorial immune checkpoint blockade therapy.Journal for immunotherapy of cancer · 2026Article
- Oncolytic Newcastle-disease-virus-mediated CD47 blockade in preclinical melanoma and pancreatic cancer models.Molecular therapy. Oncology · 2025Article
- Cancer cells accelerate exhaustion of persistently activated mouse CD4Oncoimmunology · 2025Article
- Sonodynamic therapy augmented by glycolysis inhibition: a novel metabolic reprogramming strategy for enhanced osteosarcoma treatment.National science review · 2025Article
- Acute neuronal cell death and neuroinflammation per se do not trigger secondary autoimmune encephalitis in mice.Scientific reports · 2025Article
- Biologically targeted dual adaptive and innate nano-Immunotherapy for clear cell renal cell carcinoma treatment.Molecular cancer · 2025Article
- Memory-promoting function of miR-379-5p attenuates CD8Journal for immunotherapy of cancer · 2025Article
- Universal Prophylactic Antitumor Vaccination Using Stem Cell Membrane-Coated Nanoparticles.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- A nanovaccine for immune activation and prophylactic protection of atherosclerosis in mouse models.Nature communications · 2025Article
- The role of mTOR activation in steroid-resistant asthma: insights from particulate matter-induced mouse model and patient studies.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Article
- Required minimal protein domain of flower for synaptobrevin2 endocytosis in cytotoxic T cells.Cellular and molecular life sciences : CMLS · 2024Article
- Cysteine-binding adjuvant enhances survival and promotes immune function in a murine model of acute myeloid leukemia.Blood advances · 2024Article
- Cystine deprivation triggers CD36-mediated ferroptosis and dysfunction of tumor infiltrating CD8Cell death & disease · 2024Article
- Bystander activated CD8Nature communications · 2024Article
- Flow cytometric analysis of immune cell populations in the bronchial and mesenteric lymph nodes of the dromedary camel.Frontiers in veterinary science · 2024Article
- Survival and division fate programs are preserved but retuned during the naïve to memory CD8Immunology and cell biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundStudies assessing immune parameters typically utilize human PBMCs or murine splenocytes to generate data that is interpreted as representative of immune status. Using splenocytes, we have shown memory CD4-T cells that expand following systemic immunostimulatory therapies undergo rapid IFNg-mediated activation induced cell death (AICD) resulting in a net loss of total CD4-T cells which correlates with elevated PD-1 expression. This is in contrast to CD8-T cells which expand with minimal PD-1 upregulation and apoptosis. In this study we expand upon our previous work by evaluating CD4 and CD8-T cell phenotype and distribution in peripheral organs which are more representative of immune responses occurring at metastatic sites following immunotherapy.
methodsPhenotypic assessment of T cells in both lymphoid (spleen and LN) as well as peripheral organs (liver and lungs) in control and immunotherapy treated mice was performed to survey the impact of location on memory phenotype and activation marker status. Peripheral blood from patients undergoing systemic high dose IL-2 was also assessed for expression of PD-1 and memory phenotype.
resultsHere we reveal that, similar to what occurs in the spleen and lymph nodes, CD4-T cell numbers decreased while CD8-T cells expanded at these peripheral sites. In contrast to having differential expression of PD-1 as occurs in the spleen, both CD4 and CD8-T cells had significantly elevated levels of PD-1 in both the liver and lungs. Further analysis correlated PD-1 expression to CD62L
conclusionsThese data highlight PD-1 expressing and/or T
trial registrationClinicalTrials.gov NCT01416831. Registered August 12, 2011.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.